Open |
S1914 |
A Randomized Phase III Trial of Induction/Consolidation Atezolizumab (NSC #783608) + SBRT versus SBRT Alone in High Risk, Early Stage NSCLC |
3/25/2020 |
|
74% |
|
|
Closed |
S1900B |
LUNGMAP S1900B: RET Fustion Positive - LOXO-292 |
2/10/2020 |
|
5% |
|
|
Closed |
S1900C |
LUNGMAP S1900C: STK11 - Talazoparib Plus Avelumab |
1/16/2020 |
12/18/2020 |
100% |
|
|
Open |
S1827 |
MRI Brain Surveillance Alone Versus MRI Surveillance and Prophylactic Cranial Irradiation (PCI): A Randomized Phase III Trial in Small-Cell Lung Cancer (MAVERICK) |
1/10/2020 |
|
32% |
|
|
Open |
S1922 |
Randomized Phase II Study of Ramucirumab and Paclitaxel versus FOLFIRI in Refractory Small Bowel Adenocarcinoma |
12/16/2019 |
|
34% |
|
|
Closed |
S1826 |
Phase III Study of AVD plus nivolumab or BV in pts >/= 12 years in newly diagnosed, advanced cHL |
7/19/2019 |
12/1/2022 |
100% |
|
|
Open |
S1803 |
PIII Daratumumab + Lenalidomide Post-Auto SCT Maint for MM |
6/27/2019 |
|
100% |
|
|
Closed |
S1916 |
Digital Medicine for Opioid Pain Control |
6/11/2019 |
|
3% |
|
|
Closed |
S1800A |
LUNGMAP S1800A: Non-Match Immunotherapy Combination Sub-Study |
5/17/2019 |
11/16/2020 |
100% |
|
|
Closed |
S1806 |
Concurrent Chemoradiotherapy with or Without Atezolizumab in Localized Muscle Invasive Bladder Cancer. |
4/19/2019 |
|
100% |
|
|
Closed |
S1714 |
CIPN |
3/1/2019 |
|
100% |
|
|
Closed |
S1600 |
Effect of Immune-Enhancing Nutrition on Radical Cystectomy Outcomes |
2/21/2019 |
10/20/2023 |
100% |
|
|
Closed |
S1614 |
Rando Prophylactic Antiviral HBV |
2/21/2019 |
11/15/2022 |
1% |
|
|
Closed |
S1900A |
LUNGMAP S1900A: LOH HIGH and/or BRCA 1/2 mutation - Rucaparib |
1/29/2019 |
|
73% |
|
|
Open |
LUNGMAP |
LUNGMAP Screening Protocol for NSCLC |
1/28/2019 |
|
|
|
|
Closed |
S1801 |
Ph II Ramdomization for Clinically Detectable Stage III-IV High-risk Melanoma |
12/6/2018 |
5/5/2022 |
100% |
|
|
Closed |
S1815 |
Phase III Randomized for advanced biliary tract cancers |
12/3/2018 |
2/15/2021 |
100% |
|
|
Open |
S1802 |
PhIII Rando SST v. SST+Surgery or Radiation for Met Prostate Cancer |
9/17/2018 |
|
63% |
|
|
Open |
S1706 |
Phase II Rando, Double Blind Placebo/Veliparib + RT for Inflammatory Breast |
9/12/2018 |
|
51% |
|
|
Closed |
S1701 |
Thymic |
8/9/2018 |
9/29/2022 |
32% |
|
|